GSK pays $1.2B upfront for Boston Pharmaceuticals’ lead liver disease drug
GSK is brushing off dropping a cancer asset on Tuesday by snagging a late-stage liver disease drug for a hefty $1.2 billion upfront.
GSK is brushing off dropping a cancer asset on Tuesday by snagging a late-stage liver disease drug for a hefty $1.2 billion upfront.
